Immunocore Holdings (IMCR) Short term Debt (2019 - 2024)
Immunocore Holdings (IMCR) posted Short term Debt of $48.2 million for Q3 2024, up 3787.35% sequentially from $1.2 million in Q2 2023.
Powered by 
Analysis
Immunocore Holdings (IMCR) Short term Debt (2019 - 2024) Analysis & Trends
Immunocore Holdings has reported Short term Debt for 3 years, with the latest figure at $48.2 million in Q3 2024.
- Quarterly Short term Debt changed N/A year-over-year to $48.2 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $48.2 million (changed N/A YoY) and the FY2019 annual result came in at $24.6 million, changed N/A from the prior year.
- Short term Debt improved to $48.2 million in Q3 2024 per IMCR's latest filing, from $1.2 million in the prior quarter.
- Over five years, Short term Debt peaked at $48.2 million in Q3 2024 and troughed at $1.2 million in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Immunocore Holdings | 1.85 Bn | 965.54 Mn | 114.84 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 48.21 Mn |
| Jun 30, 2023 | 1.24 Mn |
| Dec 31, 2019 | 24.63 Mn |